I’m staying out of VRTX: the supplied data do not show cash balances, debt maturities or interest coverage, so I cannot verify that it can weather a bad year without raising capital. Debt/equity is 0.31, but its 192.5% year-over-year increase is a warning to investigate, not proof of distress. Q3 revenue grew 11.8% to $3,441M, yet net income fell 39.6% to $654M and free cash flow dropped 52.1% to $546M, weakening the evidence of near-term financial resilience. The shares also cost 35.2x trailing earnings and 27.4x estimated 2027 earnings; that premium leaves little room for a balance-sheet blind spot. Analysts see 11.4% median upside, but I need liquidity and debt-service data before committing cash. I hold no position, so I stay out rather than buy on incomplete evidence.
How it picked this company
- Searched: S&P 500 · Healthcare · USD · largest first
I’m screening large U.S. healthcare companies for cash-rich, manageable-debt businesses that can fund obligations through a downturn, with GILD worth checking beyond its headline EPS growth.
- 15 matches
- Compared: VRTX, ISRG
Both appear to have strong cash generation and relatively low reliance on borrowing, making them promising candidates for a closer review of cash, debt, and maturities.
- Chose this one:
Vertex is the stronger balance-sheet fit: it has substantial cash and little to no financial debt, supporting resilience without relying on capital markets. Intuitive Surgical is also financially sound, but Vertex’s lower valuation offers a better margin of safety.